Natco Pharma Ltd. — Major Shareholding Notification 2026

Apr 29, 2026

NATCO

Natco Pharma Limited

Regd. Off.: NATCO HOUSE, Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

April 3, 2026

Corporate Relationship Department
M/s. BSE Ltd
Mumbai 400 001

The Manager – Listing
M/s. National Stock Exchange of India Ltd
Bandra (E) Mumbai 400 051

Scrip Code: 524816
Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosures under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Please find enclosed herewith the Disclosures received from Sri V.C. Nannapaneni, Promoter and on behalf of other Promoters, Members of Promoter Group and Persons Acting in concert under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the Financial year ended March 31, 2026.

Thanking you

Yours faithfully
For NATCO Pharma Limited

VENKAT RAMISH
CHENUR
AUTHORIZED SIGNATURE

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

---

Chowdary V. Nannapaneni

NATCO HOUSE, Road No. 2, Banjara Hills, Hyderabad - 500 033. INDIA. Tel: +91 40 23547532 Fax: +91 40 23545298

April 4, 2026

Corporate Relationship Department
M/s. BSE Ltd
Mumbai 400 001

The Manager – Listing
M/s. National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: 524816
Scrip Code: NATCOPHARM

Dear Sir

Sub:- Disclosures under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

With reference to the above cited subject, I hereby confirm that the shares held in NATCO Pharma Limited by me, Promoter(s)/ Members of the Promoter Group and Persons Acting in concert were not encumbered/pledged directly or indirectly during the Financial Year ended March 31, 2026.

This is for your information and records.

Thanking you

cc to: The Audit Committee
NATCO Pharma Limited